Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
US-backed Gaza aid group launches bold new system...
Biden doctor pleads the Fifth in speedy House...
Watchdog backs Rubio’s sanctions on UN official over...
Trump taps Sean Duffy to serve as interim...
Trump cautioned Putin he would ‘bomb the s—‘...
I worked for the most successful third party...
‘Gut check time’: Dissent among Senate GOP ranks...
New book reveals what Obama and ‘conqueror’ Trump...
Trump had very unexpected convo with Obama at...
10 reasons the DOJ and FBI face backlash...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Zero Candida Technologies:Pioneering Technology-driven, Innovative Solution for Non-drug Treatment of Candidiasis

by admin December 18, 2024
December 18, 2024
Zero Candida Technologies:Pioneering Technology-driven, Innovative Solution for Non-drug Treatment of Candidiasis

Founded by a team of seasoned entrepreneurs and healthcare experts, Zero Candida (TSXV:ZCT) is a fem-tech pioneer, combining advanced artificial intelligence with non-drug diagnostics and personalized treatment modalities in a single device. The company developed an innovative, first-of-its-kind solution to the diagnosis and treatment of Candidiasis, a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva. The device offers precision therapy by eliminating fungal infections with over 99.99 percent effectiveness in just three hours, a revolutionary improvement over existing treatments.

Zero Candida is on track to complete clinical trials and file for FDA approval in 2024 with its innovative technology.

Zero Candida’s SMART vaginal diagnostic device utilizes blue light therapy to treat this widespread condition without drugs. This non-drug therapy addresses key issues associated with conventional antifungal medications, including reduced risk of drug resistance, minimized side effects, and potential for faster symptom relief

Company Highlights

  • Zero Candida Technologies is a fem-tech company focused on developing a SMART diagnostic and therapeutic device aimed at eliminating vaginal candidiasis (commonly known as yeast infection), a condition that affects three out four women globally.
  • Candidiasis a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva. In several cases, the current treatment for Candidiasis has been ineffective.
  • Zero Candida has completed proof-of-concept studies, and demonstrated near-complete fungal eradication with over 99.99 percent effectiveness in just three hours.
  • Founded by a team of experienced entrepreneurs and healthcare experts, the company is addressing the significant unmet needs of the women’s health market.
  • The fem-tech segment of the med tech market is expected to grow at a CAGR of 18.2 percent and is estimated to reach nearly US$30 billion by 2032. North America dominated the global fem-tech market with a share of 52.91 percent in 2023.
  • The company has already patented this technology in South Africa, while additional filings for patent application in the US and EU are underway.

This Zero Candida profile is part of a paid investor education campaign.*

Click here to connect with Zero Candida (TSXV:CZT) to receive an Investor Presentation

This post appeared first on investingnews.com

previous post
Women’s basketball league Unrivaled secures $28M in funding from star-studded investor lineup
next post
First Helium Provides Year End Corporate Update

You may also like

Galan Lithium

August 5, 2024

5 Experts Share Highest-Conviction Sectors for 2025

January 4, 2025

COLDry Fertiliser JV Seed Funding & Working Capital...

December 18, 2024

Critical One Sells Uranium Assets to Dark Star,...

June 17, 2025

Ontario Backs Down on Key Bill 5 Provisions,...

May 31, 2025

2024 Annual Results – Capacity ramp-up, economies of...

February 28, 2025

Lode Gold Launches Exploration Program at One of...

October 19, 2024

FPX Nickel Scoping Study for North America’s Largest...

February 24, 2025

Google’s New Pixel Devices Promise Enhanced AI Capabilities

August 15, 2024

Forum Announces Final Assay Results from Tatiggaq; Drill...

January 13, 2025

Recent Posts

  • US-backed Gaza aid group launches bold new system to deliver food directly to families
  • Biden doctor pleads the Fifth in speedy House closed-door interview
  • Watchdog backs Rubio’s sanctions on UN official over ‘shameful efforts’ targeting US, Israel
  • Trump taps Sean Duffy to serve as interim NASA chief
  • Trump cautioned Putin he would ‘bomb the s—‘ out of Moscow if Russia invaded Ukraine, new book claims

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (819)
    • Investing (2,497)
    • Politics (3,095)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.